Irwin Naturals Inc. (OTC:IWINF) has terminated the non-binding amended and restated letter of intent (LOI) for a business combination with medical research and telemedicine company Braxia Scientific Corp. (OTC:BRAXF).
CEO Klee Irwin said the decision was based on a "lack of a clear business rationale" for the company to move forward with the transaction.
See also: Irwin Naturals Secures $40M To Accelerate Expansion Of Its Psychedelic Mental Health Clinics
Braxia CEO Dr. Roger McIntyre said the company is "disappointed" with the decision by Irwin and the impossibility to complete the transaction, adding that the team "remains well positioned as global leaders in depression and ketamine research, with high quality, trusted clinics and a telemedicine platform launched in the US."
Braxia will retain its strategic assets across three business verticals, including clinical operations in Canada, US-based telemedicine platform KetaMD, and international clinical research infrastructure.
Benzinga Psychedelics Capital Conference
The second edition of the Benzinga Psychedelics Capital Conference is coming your way! The event will take place at the Fontainebleau Miami Beach Hotel in Florida on April 13, 2023. This is THE place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.
Get your tickets now before prices go up.
Photo: Benzinga edit with photo by True Touch Lifestyle on Shutterstock and Wikimedia Commons.
亞洲網加利福尼亞州聖約瑟10月23日電爾文自然公司(場外交易代碼:IWINF)已經終止了與醫學研究和遠端醫療公司布拉夏科學公司(場外交易代碼:BRAXF)進行業務合併的不具約束力的修訂和重述意向書(LOI)。
首席執行官克利·爾文表示,這一決定是基於該公司推進這筆交易的“缺乏明確的商業理由”。
另見:爾文自然公司獲得4000萬美元,以加快其迷幻精神健康診所的擴張
BraxiaCEO羅傑·麥金太爾博士該公司表示,公司對爾文的決定和無法完成交易感到“失望”,並補充說,該團隊“仍然是抑鬱症和氯胺酮研究領域的全球領導者,擁有高質量、值得信賴的診所和在美國推出的遠端醫療平臺。”
Bracia將保留其在三個垂直業務領域的戰略資產,包括加拿大的臨床業務、總部位於美國的遠端醫療平臺KetaMD和國際臨床研究基礎設施。
本辛加迷幻藥資本大會
這個本辛加迷幻藥資本會議第二版正在向你走來!活動將於2023年4月13日在佛羅裡達州的楓丹白露邁阿密海灘酒店舉行。這裡是達成交易、籌集資金、啟動並購、會見投資者和關鍵合作夥伴的地方。
趁還沒漲價,現在就買票吧。
圖片:Benzinga在Shutterstock和Wikimedia Commons上編輯了True Touch Lifestyle的照片。